![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 53, 38107-38111, December 31, 1999
From The Wellcome Trust Centre for Cell Matrix Research, School of
Biological Sciences, University of Manchester,
Manchester M13 9PT, United Kingdom
Aggrecan is a multidomain proteoglycan containing
both extended and folded protein modules. The C-terminal G3 domain
contains a lectin-like, complement regulatory protein-like, and two
alternatively spliced epidermal growth factor-like modules. It has been
proposed that the lectin module alone has a necessary role in the
intracellular translocation and secretion of proteins expressed
containing G3. Constructs containing human aggrecan G3 together with
1155 bases of the adjacent chondroitin sulfate attachment region (CS-2)
were prepared with different combinations and deletions of the protein modules and transfected into mammalian cells of monkey or hamster origin. The results showed that the products containing only the unfolded protein sequences (CS-2 with or without the C-terminal tail
sequence) were translated and accumulated intracellularly but were not
secreted. In contrast the constructs containing any of the folded
protein modules and the extended CS-2 region were translated and
secreted from the cells. The results show that the lectin module was
not unique in facilitating the intracellular translocation and
secretion of the G3 domain. The conservation of G3-like domains within
the aggrecan family of proteoglycans may therefore result from their
participation in other extracellular functions.
Aggrecan is a large multidomain proteoglycan produced by
chondrocytes and found as an essential component of the extracellular matrix of cartilage (1). The protein core consists of three globular
and two extended domains. There is an N-terminal G1 domain that
interacts specifically with hyaluronan to form multimolecular aggregates in which up to 100 aggrecan molecules bind to each hyaluronan chain (2). In contrast, the C-terminal G3 domain has no
clearly established function. It consists of a C-type lectin module, a
complement regulatory protein-like module and two alternatively spliced
EGF1-like modules. Its
structure is highly conserved among aggrecans in different species, and
closely related structures are present in other members of this family
of proteoglycans, versican, neurocan, and brevican (3). Its possible
functions include both carbohydrate (4-6) and protein ligand (7)
interactions in the extracellular matrix, but it has also been proposed
to have intracellular functions (8, 9).
The cause of nanomelia in the chicken was identified as a mutation in
the aggrecan gene that produced a premature stop codon in the extended
CS-2 chondroitin sulfate attachment region (10). This resulted in the
synthesis of aggrecan lacking the normal C-terminal G3 structure, and
although the protein was translated and present intracellularly in
chondrocytes, it was not fully glycosylated or secreted (11, 12).
Cartilage is an essential forerunner of skeletal development in the
embryo, and in the nanomelic chick the lack of aggrecan stunted
cartilage development and long bone formation.
These observations led to the proposal that the G3 domain was necessary
intracellularly for the translocation and secretion of aggrecan.
Expression of chicken aggrecan G3 in Chinese hamster ovary cells showed
that the G3 domain was much more efficient than the G1 domain in
facilitating the secretion of an extended CS attachment sequence, and
this was independent of its position 5' or 3' to the extended sequence
(13). Further refinement showed that the removal of the CRP module gave
no loss of this activity, and finally, it was also shown that of the
remaining LEC coding sequence, only the second of the three exons was
necessary in the structure to ensure secretion of the product (9). From these results it was concluded that the LEC module was essential for
aggrecan biosynthesis, to facilitate its intracellular translocation, and secretion. To follow up these results, in this study the secretory behavior of a larger range of constructs based on the human aggrecan G3
domain have been investigated after their transfection into mammalian
cells of monkey or hamster origin.
Reverse Transcriptase PCR--
Total RNA was extracted with
Tri-Reagent (Sigma) from a sample of human articular cartilage (kindly
provided by Glynne Andrew, Hope Hospital, Salford, UK). Random-primed
reverse transcriptase (RT) product was amplified with primers Agg 4 and
Agg 11 (see Fig. 1 for primer details) in a PCR. The human EGF1
sequence was found in a 495-bp product. EGF2 cDNA was amplified
using an overlapping primer PCR method (14) with primers based on the
human EGF2 sequence (15). Primers Agg 4 and Agg 13 (inverse complement of bases 47 to 64 of the EGF2 sequence) were used to amplify the 5'
half of the EGF2 cDNA and 177 bp of the flanking upstream CS-2 chondroitin sulfate attachment region. Primers Agg 12 (bases 47 to 64 of the EGF2 sequence) and Agg 11 were used to amplify the 3' half of
the EGF2 motif cDNA and 204 bp of the downstream lectin-like motif.
The final PCR product, amplified with primers Agg 4 and Agg 11, was a
cDNA containing the EGF2 motif as though it had been alternatively
spliced into the aggrecan mRNA. A cDNA containing both EGF
motifs was prepared using a primer containing 20 bp at the 3' end of
the EGF1 motif and 20 bp at the 5' end of the EGF2 motif and another
primer containing the inverse complementary sequence. Human aggrecan
signal sequence cDNA was amplified from the same total RNA pool by
RT-PCR using primers Agg 18 (situated in the 5'-untranslated region of
the published human aggrecan cDNA (16), bases 13 to 30 with an
additional 5' HindIII restriction enzyme site) and Agg 19 (inverse complement of bases 106 to 123 of the same sequence, with
Glu-21 providing the GAA of an additional EcoRI restriction
enzyme site).
Assembly of G3 Variant Constructs--
To construct a panel of
cDNAs containing varying combinations of the folded motifs present
in the G3 domain, a human aggrecan cDNA encoding the C-terminal 385 amino acids of the CS-2 region, the LEC, CRP and tail motifs (17) was
inserted into the EcoRI site of pBluescript KS (Stratagene)
from which the XbaI and HincII sites had been
deleted (Fig. 1A). EGF sequences were inserted by digesting
the RT-PCR products described above with XbaI and HincII and ligating these into the corresponding restriction
sites in the original aggrecan cDNA. Constructs in which the LEC
and CRP motifs were deleted either singly or together were made using an overlapping primer PCR method (14) using plasmids as template. Each
construct required two specific primers, one containing the last 20 bp
of the first motif and the first 20 bp of the second motif to be joined
together. The other specific primer was the inverse complementary
sequence of the first. The sequence of the primers at the transition
between motifs followed the predicted exon boundaries (18) as though
the motifs had been alternatively spliced. The other primers used for
the PCR were Agg 4, Agg 1, and the T3 primer from the Bluescript vector
(Fig. 1A). PCR products and parent plasmids were digested
with the appropriate restriction enzymes and ligated together to
produce the panel of constructs shown in Fig. 1. Constructs were
released from the Bluescript vector by digestion with EcoRI
and subcloned into the expression vectors pcS or pcA.
Vector pcS was derived from the mammalian expression vector pcDNA3
(Invitrogen) by replacing the cytomegalovirus promoter region with an
NruI and BamHI fragment of the Sig pIg vector (R & D Systems) containing the cytomegalovirus promoter and the sequence encoding the CD33 signal peptide. To make vector pcA, human aggrecan signal sequence RT-PCR product (as described above), digested with
HindIII and EcoRI, was subcloned into pcDNA3
digested with the same enzymes, placing the aggrecan AUG translation
initiation codon under the control of the cytomegalovirus promoter of
the vector. Insert CS (Fig. 1B) was made by digesting
pcS.CS.L.C.t with XbaI, which removed the last 43 amino
acids of the CS-2 region, the entire G3 region, and cuts in the
multiple cloning site of the pcS vector at the 3' end of the insert.
Re-ligation of these XbaI sites fused 23 amino acids encoded
by the pcS multiple cloning site onto the truncated CS-2 region. This
was the only construct with any non-native sequence. All constructs
were sequenced to verify in-frame addition of signal sequences and
correct sequences across newly constructed motif junctions. In
addition, all constructs were translated in a cell-free
transcription/translation system (TNT-coupled transcription/translation
system; Promega) to confirm full-length translation products.
Cell Culture and Transfection--
COS-1 cells (American Type
Culture Collection) were grown in Dulbecco's modified Eagle's medium
(Life Technologies, Inc.) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, penicillin (100 IU/ml), and
streptomycin (100 (g/ml) in a humidified atmosphere (5%
CO2) at 37 °C. Cells were transfected at ~60%
confluency with plasmid DNA (5 µg/60-mm culture dish) using
DEAE-dextran (Promega) in chloroquine-containing medium for 4 h.
Fresh medium was applied, and the following day the cells were
incubated in medium (as above) containing 0.5% fetal bovine serum for
a further 48 h.
Embryonic Syrian hamster cells (DES4+.2) transformed with
diethylstilbestrol (19, 20) were grown in minimum essential medium
(Life Technologies) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, penicillin (100 IU/ml),
streptomycin (100 (g/ml), and minimum essential medium nonessential
amino acids (1×) (Life Technologies, Inc.). Cells were transfected at
~70% confluency with plasmid DNA (5 µg/60-mm culture dish) in
Pfx-5 lipid solution (Invitrogen) in serum-free medium for 4 h.
The transfection medium was replaced with complete culture medium for
18-24 h and then replaced with medium (as above) containing 0.5%
fetal bovine serum for 48 h incubation. The harvested medium was
centrifuged at 1000 × g for 2 min, and protease
inhibitors were added (1 mM EDTA, 2 mM
phenylmethylsulfonyl fluoride, 10 mM
N-ethylmaleimide, 0.5 µg/ml leupeptin, 1 µg/ml antipain,
5 µg/ml benzamidine HCl, 0.5 µg/ml aprotinin, 0.5 µg/ml
chymostatin, and 0.5 µg/ml pepstatin). It was dialyzed against
deionized water at 4 °C, freeze-dried, dissolved in chondroitinase
ABC digestion buffer (0.01 M Tris-HCl, pH 7.4, 0.15 M NaCl) and stored at SDS-PAGE and Immunoblotting--
Samples from medium and cell
extracts were electrophoresed under reducing conditions in 7.5%
SDS-PAGE gels (21), in 4-20% gradient SDS-PAGE gels (Bio-Rad), or in
NuPAGE 4-12% Bis-Tris gels (NOVEX), transferred to nitrocellulose
membranes (22) (with Tris-Bicine transfer buffer (NOVEX) for Nu-PAGE
gels), and blocked in 10 mM phosphate-buffered saline (138 mM NaCl, 2.7 mM KCl, pH 7.4) containing 4%
nonfat dried milk powder. Transfer was confirmed by Ponceau R staining.
Immunodetection of expressed products was carried out with JD5, a
rabbit polyclonal antiserum raised against a bacterial
GST.CS2.LEC.CRP.t fusion protein (17) and also with mouse monoclonal
antibodies, 1B5, 2B6, and 3B3, which recognize nonsulfated, 4-sulfated,
and 6-sulfated chondroitin sulfate chains, respectively, after
chondroitinase ABC digestion (23). Bound antibody was detected with
horseradish peroxidase-conjugated anti-rabbit or anti-mouse secondary
antibodies and chemiluminescence (NEN Life Science Products).
Immunoblots were quantitated using a GS-700 imaging densitometer and
Molecular Analyst software (Bio-Rad). The integrated optical density
was determined for each band and corrected for background. For each
construct the percentage of product secreted was calculated for three
separate transfections from blots with nonsaturating densities and in a
range that showed a linear correlation with loading.
Constructs based on a cDNA coding for the C-terminal third of
the human aggrecan mRNA were prepared in a vector, pcS, based on
pcDNA3 (Invitrogen). This cDNA sequence included a major part (1155 bp) of the CS-2 chondroitin sulfate attachment region (CS) with
27 potential CS attachment sites, the C-lectin-like module (L), the
complement regulatory protein-like module (C), and the natural short
(74 bp) C-terminal sequence (t). This CS.L.C.t sequence (Fig.
1) is the form found most commonly in
chondrocyte aggrecan mRNA and lacks the two alternatively spliced
EGF-like modules (16). The vector contained a signal sequence from the
protein CD-33 to direct protein translation to membrane-bound ribosomes and into the secretory pathway. Other cDNA constructs were prepared with deletions of each of the LEC and CRP modules and with inserted EGF-1 (E1) and EGF-2 (E2) modules generated by RT-PCR from human chondrocyte mRNA. This provided a range of constructs containing the CS-2 region and a variable number of folded protein modules (Fig.
1). All the constructs were prepared with the folded protein modules
delineated with junctions at the natural exon boundaries.
The constructs were assessed initially by in vitro
translation, and all gave protein products; however, many appeared to
be larger than expected on SDS-PAGE. As only a construct lacking the
CS-2 region was of the expected size (not shown), it appeared that
anomalous migration was a property of the CS-2 region. This may result
from poor binding of SDS by this protein region or possibly because it
has an extended or stiffened conformation. It increased the apparent
mass of all products containing the CS-2 region by about 40 kDa in the
electrophoresis system used, but it was also observed with CS-2
products from in vitro translation. The anomalous migration
was therefore not a result of the glycosylation of CS-2.
Initial transfection studies were carried out in COS-1 cells (monkey
origin). Transfection of the basic CS.L.C.t construct with DEAE-dextran
produced transient expression, which was investigated by immunoblotting
of cell layer and medium samples after SDS-PAGE (Fig.
2). The results showed that the protein
was synthesized and secreted and was well detected by the antiserum in
the cell layer and in the medium after culture for 48 h. The
separate removal of either of the LEC or CRP modules had no significant
effect on synthesis and secretion in transfected cells. However,
constructs containing the CS-2 region but lacking both LEC and CRP
modules (CS.t and CS) were much less abundant in the medium at 48 h, although they were well expressed in the cell layer. The relatively
long culture time used for these analyses showed a clear distinction between protein products that were secreted into the medium (80-90% in the medium in 48 h) and products that appeared intracellularly but were not efficiently secreted into the medium (<10% in the medium
in 48 h). This established a pattern of synthesis and secretion in
which the presence of either the LEC or the CRP module was necessary
for the efficient secretion of a CS-2 region (Table I).
The Folded Protein Modules of the C-terminal G3 Domain of
Aggrecan Can Each Facilitate the Translocation and Secretion of the
Extended Chondroitin Sulfate Attachment Sequence*
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
20 °C. Total RNA was extracted
from COS-1 and DES4+.2 cell layers in Tri-Reagent (Sigma), and cellular
proteins were isolated from the organic phase of the extract using the
manufacturer's alternative procedure. The volumes of cell protein
extracts were adjusted to those of the medium samples by centrifugal
evaporation, and 10× chondroitinase digestion buffer was added to
ensure that comparisons were made between equal fractions of the total
medium and the total cell layer extract. Chondroitin ABC lyase (Sigma)
digestion of medium and cell layer extract samples was with 1.5 units/ml at 37 °C for 3 h, and in a similar buffer, digestion
of N-linked oligosaccharides was with 0.23 units/ml
endoglycosidase F, 0.29 units/ml peptide N-glycosidase F
(Oxford Glycosciences, Abingdon, UK) incubated at 37 °C for 18 h.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (18K):
[in a new window]
Fig. 1.
Diagram of construct assembly details and
panel of the human aggrecan G3 cDNA variants. A,
strategy for the assembly of G3 domain variants. The boundaries of the
motifs are shown within the original cDNA (dashed vertical
lines). Also shown are the positions of the major primers used for
RT-PCR and PCR amplifications and the restriction enzyme sites used in
the construction of the cDNA variants. Primers Agg 1, 4, and 11 were based on the aggrecan cDNA sequence C4 (16) at Agg 1 (bases
1259 to 1278), Agg 4 (bases 980 to 997), Agg 11 (the inverse complement
of bases 1343 to 1360). B, schematic of the translated
products of the cDNAs with the annotation describing their
composition. MCS, multiple cloning site.

View larger version (19K):
[in a new window]
Fig. 2.
Expression of aggrecan G3 cDNA constructs
in COS-1 cells. Samples of culture medium (M) and cell
layer extract (I) with (+) or without (
) digestion with
chondroitinase ABC lyase were separated by SDS-PAGE, transferred, and
immunolocalized with JD5 polyclonal antiserum (as described under
"Experimental Procedures").
Secretion of aggrecan constructs by COS-1 cells
Having obtained this result in COS-1 cells, the pattern of secretion
was also investigated in DES4+.2 cells. These cells are derived from
Syrian hamster embryonic stem cells by mutagenesis (19) and have been
characterized as chondrocyte-like as they express collagen type II and
IX mRNAs (20). Transfection of these cells with the various
constructs showed a pattern of secretion similar to that of COS-1 cells
(Fig. 3). Only the constructs containing the CS-2 region but lacking a folding protein module failed to be
efficiently secreted. The addition of EGF-1 or -2 modules to the
construct with the CS-2 region and both LEC and CRP modules again
resulted in the synthesis and secretion of the product. Even the
addition of a single EGF-1 module to the CS-2 region was sufficient to
give secretion of the protein into the medium well above that observed
with CS-2 region alone, although over a number of transfections it
appeared less efficient than with the other protein modules. This
pattern of secretion of products was consistent between transfection
experiments with DES4+.2 cells and COS-1 cells. The extended CS-2
region was poorly translocated and secreted if expressed on its own or
together with the natural C-terminal sequence (t), but if it was
attached to any of the folded protein modules in the G3 domain, this
was sufficient to permit its translocation and secretion. However, no
specific module was required for this to occur.
|
In further transfection experiments in DES4+.2 cells, the CD33 signal sequence in the construct was replaced by the natural aggrecan signal sequence, but this had no effect on synthesis, or secretion, or on the apparent size of the products (not shown). There was therefore no suggestion that the signal sequence was responsible for directing the translated protein into different pathways.
The size of the products expressed in transfected cells was larger than
those produced by cell-free translation, and the size of most of the
expressed products secreted in the medium of both cell types was larger
than that in the cell layer (Fig. 4).
These differences in size are likely to result from various
processes of glycosylation in the rough endoplasmic reticulum and
Golgi regions during translocation through the secretory pathway. The level of chondroitin sulfate synthesis on the secreted products was
low, as chondroitinase ABC digestion only sharpened the main bands but
caused little reduction in their apparent size (Figs. 2-4). The
digested products were reactive with chondroitin sulfate monoclonal
antibodies (23) (Fig. 5A) and
most reactive with that specific for 4-sulfated terminal disaccharide
groups (Fig. 5B). The level of chondroitin sulfate also
showed no significant variation with constructs of different protein
module composition. It thus appeared that only a fraction of the
secreted products received some chondroitin sulfate chains during
synthesis. A minor product band of faster mobility, which was reactive
with the aggrecan antiserum and with CS antibodies, was seen with
different constructs most prominantly in DES4+.2 cells (Fig. 3) and is
likely to result from differences in glycosylation among the secreted
products. The medium from the DES4+.2 cells contained additional bands
of higher molecular weight reactive with the chondroitin sulfate monoclonal antibodies (Fig. 5, A and B). These
bands were present in the medium from nontransfected control cells, but
they did not react with the aggrecan specific JD5 antiserum (Fig.
5A) and are therefore other proteoglycans. The cell layer
products from transfected cells were not affected by chondroitinase
digestion and were unreactive with CS antibodies, showing that they had no chondroitin sulfate attached. Digestion of the cell layer product from cells transfected with the CS.L.C.t construct with enzymes (endoglycosidase-F/peptide N-glycosidase F) that remove
N-linked oligosaccharides reduced its size to that of the
cell-free translation product (Fig. 4). Similar treatment of the
secreted product after chondroitinase ABC digestion also reduced its
size, but it remained significantly larger than the digested cell layer
product.
|
|
| |
DISCUSSION |
|---|
|
|
|---|
These results with human aggrecan cDNA constructs expressed in mammalian cells show that, as in the nanomelic chick, the extended CS-2 sequence is not translocated or secreted without a C-terminal folded protein motif. In the current study care has been taken in the preparation of constructs to splice all sequences of the folded protein modules at natural junctions to avoid interfering with their secondary or tertiary structure. Under these conditions, any of the protein modules predicted to fold in the G3 domain (24) were able to facilitate secretion of the adjacent CS-2 region, and there was little detectable difference between the LEC and CRP modules in this function. These experiments on human aggrecan G3 expression show some results that differ from those reported (9) on chicken aggrecan G3 expression in Chinese hamster ovary cells, from which it was concluded that the LEC module was essential for the secretion of G3 constructs. In support of this, the interaction of the LEC module with chaperone Hsp-25 was demonstrated, and this highlighted the potentially important function of the chaperone in the folding of the LEC module and in facilitating its translocation to the Golgi and subsequent secretion. However, from the present results, the secretory role of LEC can be replaced by CRP and at least partly by the EGF modules. These protein modules may also interact with chaperones in the process of folding, and this may similarly facilitate secretion.
Previous studies on aggrecan synthesis in chondrocytes have shown the protein to be in the ER for 20-30 min, during which N-linked oligosaccharides are synthesized (25). This is followed by more rapid translocation through the Golgi and by secretion within 5-10 min (26). Much evidence shows the addition of chondroitin sulfate and O-linked oligosaccharides to occur in the medial-trans-Golgi (27). The absence of any attached chondroitin sulfate in the cell layer product (Fig. 5A) suggests that most of the molecules in this fraction are in the ER and have not yet reached the medial/trans Golgi. The cell layer product was also shown to contain N-linked oligosaccharides, which supported its location within the ER and explained its increased size compared with the cell-free product. The size of the chondroitinase-digested culture medium product was reduced by the removal of N-linked oligosaccharides, but it remained larger than the cell layer product. This difference in size is likely to result from the residual chondroitin sulfate linkage region sugars and the presence of other O-linked oligosaccharides synthesized during transit through the Golgi before secretion. The relatively low level of chondroitin sulfate synthesis on the expressed constructs in both COS-1 cells and DES4+.2 cells may reflect a limited capacity for chondroitin sulfate synthesis. Neither cell type showed high endogenous levels of [35S]sulfate incorporation into proteoglycans (not shown). The amount of proteoglycan expressed in the transfected cells was therefore possibly too high for the efficient attachment of chondroitin sulfate. However, this is unlikely to have affected the pattern of secretion observed in this study, as transfection of chicken aggrecan G3 constructs in cells deficient in glycosaminoglycan synthesis has previously been shown to give similar results to transfection in normal cells (13).
There are clearly important mechanisms within the cell (28, 29) that prevent unfolded proteins from leaving the rough endoplasmic reticulum and progressing along the secretory pathway when they have been miss-translated, miss-spliced, or are from a defective gene, such as the nanomelic chick aggrecan. The expression of proteins with unfolded and extended sequences may require protection from such mechanisms. In this study the presence of a single folded protein module attached C-terminal to the extended and unfolded CS-2 sequence appeared sufficient to avoid this surveillance and rejection mechanism. In this family of proteoglycans the extended sequences are positioned between folded domains. In their normal biosynthesis this structural arrangement may ensure that they avoid being mistaken for incorrectly expressed products. The capping of extended sequences with folded domains in secretory proteins may have evolved as part of a prerequisite for normal secretion.
The results suggest that the LEC module in aggrecan G3 domain is not
essential for aggrecan intracellular translocation and secretion. It is
therefore likely that it is highly conserved within the C-terminal
domains of the aggrecan family of proteoglycans for other reasons.
Calcium-dependent interaction of the LEC module of all
members of this family has been shown to occur with tenascin-R by
binding to the fibronectin type III repeats (7). Calcium-dependant interactions with carbohydrate ligands have also been detected (4-6).
The LEC, CRP, and EGF-like modules may therefore together contribute to
extracellular functions of the G3-like domains of the aggrecan family,
and the alternative splicing of EGF-1 and EGF-2 may occur to modulate
these functions.
| |
ACKNOWLEDGEMENT |
|---|
Support from The Wellcome Trust is gratefully acknowledged.
| |
FOOTNOTES |
|---|
* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence and reprint requests should be addressed:
Wellcome Trust Centre for Cell-Matrix Research, School of Biological
Sciences, University of Manchester, 2.205 Stopford Bldg., Oxford Rd.,
Manchester M13 9PT, UK. Tel.: 44-161-275-5511; Fax: 44-161-275-5082;
E-mail: tharding@fs1.scg.man.ac.uk.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: EGF, epidermal growth factor; RT, reverse transcriptase; PCR, polymerase chain reaction; LEC, C-type lectin; CRP, complement regulatory protein; bp, base pair(s); PAGE, polyacrylamide gel electrophoresis; Bicine, N,N-bis(2-hydroxyethyl)glycine; CS, chondroitin sulfate attachment region.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Hardingham, T. E., and Fosang, A. J. (1992) FASEB J. 6, 861-870[Abstract] |
| 2. | Hardingham, T. E., and Muir, H. (1972) Biochim. Biophys. Acta 279, 401-405[Medline] [Order article via Infotrieve] |
| 3. |
Ruoslahti, E.
(1996)
Glycobiology
6,
489-492 |
| 4. |
Halberg, D. F.,
Proulx, G.,
Doege, K.,
Yamada, Y.,
and Drickamer, K.
(1988)
J. Biol. Chem.
263,
9486-9490 |
| 5. |
Saleque, S.,
Ruiz, N.,
and Drickamer, K.
(1993)
Glycobiology
3,
185-190 |
| 6. |
Miura, R.,
Aspberg, A.,
Ethell, I. M.,
Hagihara, K.,
Schnaar, R. L.,
Ruoslahti, E.,
and Yamaguchi, Y.
(1999)
J. Biol. Chem.
274,
11431-11438 |
| 7. |
Aspberg, A.,
Miura, R.,
Bourdoulous, S.,
Shimonaka, M.,
Heinegård, D.,
Schachner, M.,
Ruoslahti, E.,
and Yamaguchi, Y.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
10116-10121 |
| 8. | Vertel, B. M. (1995) Trends Cell Biol. 5, 458-464 |
| 9. |
Zheng, J.,
Luo, W.,
and Tanzer, M. L.
(1998)
J. Biol. Chem.
273,
12999-13006 |
| 10. |
Li, H.,
Schwartz, N. B.,
and Vertel, B. M.
(1993)
J. Biol. Chem.
268,
23504-23511 |
| 11. | Vertel, B. M., Walters, L. M., Grier, B., Maine, N., and Goetinck, P. F. (1993) J. Cell Sci. 104, 939-948[Abstract] |
| 12. | Vertel, B. M., Grier, B. L., Li, H., and Schwartz, N. B. (1994) Biochem. J. 301, 211-216 |
| 13. |
Luo, W.,
Kuwada, T. S.,
Chandrasekaran, L.,
Zheng, J.,
and Tanzer, M. L.
(1996)
J. Biol. Chem.
271,
16447-16450 |
| 14. | Horton, R. M., Hunt, H. D., Ho, S. N., Pullen, J. K., and Pease, L. R. (1989) Gene 77, 61-68[CrossRef][Medline] [Order article via Infotrieve] |
| 15. |
Fülöp, C.,
Walcz, E.,
Valyon, M.,
and Glant, T. T.
(1993)
J. Biol. Chem.
268,
17377-17383 |
| 16. |
Doege, K.,
Sasaki, M.,
Kimura, T.,
and Yamada, Y.
(1991)
J. Biol. Chem.
266,
894-902 |
| 17. | Dudhia, J., Davidson, C., Wells, T., Vynios, D., Hardingham, T., and Bayliss, M. (1996) Biochem. J. 313, 933-940 |
| 18. | Valhmu, W., Palmer, G. D., Rivers, P. A., Ebara, S., Cheng, J-F., Fischer, S., and Ratcliffe, A. (1995) Biochem. J. 309, 535-542 |
| 19. |
McLachlan, J. A.,
Wong, A.,
Degen, G. H.,
and Barrett, J. C.
(1982)
Cancer Res.
42,
3040-3045 |
| 20. | Cizdziel, P. E., Hosoi, J., Montgomery, J. C., Wiseman, R. W., and Barrett, J. C. (1991) Mol. Carcinog. 4, 14-24[Medline] [Order article via Infotrieve] |
| 21. | Laemmli, U. K. (1970) Nature 227, 680-685[CrossRef][Medline] [Order article via Infotrieve] |
| 22. |
Towbin, H.,
Staehelin, T.,
and Gordon, J.
(1979)
Proc. Natl. Acad. Sci. U. S. A.
76,
4350-4354 |
| 23. | Couchman, J. R., Caterson, B., Christner, J. E., and Baker, J. R. (1994) Nature 307, 650-652 |
| 24. | Brissett, N. C., and Perkins, S. J. (1998) Biochem. J. 329, 415-424 |
| 25. | Kimura, J. H., Lohmander, S., and Hascall, V. C. (1984) J. Cell. Biochem. 26, 261-278[CrossRef][Medline] [Order article via Infotrieve] |
| 26. | Campbell, S. C., and Schwarz, N. B. (1988) J. Cell Biol. 28, 2191-2202 |
| 27. |
Ratcliffe, A.,
Fryer, P. R.,
and Hardingham, T. E.
(1985)
J. Cell Biol.
101,
2355-2365 |
| 28. | Amara, J. F. (1992) Trends Cell Biol. 2, 145-149[CrossRef][Medline] [Order article via Infotrieve] |
| 29. | Hammond, C., and Helenius, A. (1995) Curr. Opin. Cell Biol. 7, 523-529[CrossRef][Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
N.-S. Seo, A. M. Hocking, M. Hook, and D. J. McQuillan Decorin Core Protein Secretion Is Regulated by N-Linked Oligosaccharide and Glycosaminoglycan Additions J. Biol. Chem., December 30, 2005; 280(52): 42774 - 42784. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Day, A. I. Olin, A. D. Murdoch, A. Canfield, T. Sasaki, R. Timpl, T. E. Hardingham, and A. Aspberg Alternative Splicing in the Aggrecan G3 Domain Influences Binding Interactions with Tenascin-C and Other Extracellular Matrix Proteins J. Biol. Chem., March 26, 2004; 279(13): 12511 - 12518. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Lee, L. Chen, F. Paiwand, L. Cao, Y. Wu, R. Inman, M. E. Adams, and B. B. Yang Cleavage of the Carboxyl Tail from the G3 Domain of Aggrecan but Not Versican and Identification of the Amino Acids Involved in the Degradation J. Biol. Chem., June 14, 2002; 277(25): 22279 - 22288. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wu, L. Chen, P.-S. Zheng, and B. B. Yang beta 1-Integrin-mediated Glioma Cell Adhesion and Free Radical-induced Apoptosis Are Regulated by Binding to a C-terminal Domain of PG-M/Versican J. Biol. Chem., March 29, 2002; 277(14): 12294 - 12301. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Domowicz, E. W. Pirok III, T. E. Novak, and N. B. Schwartz Role of the C-terminal G3 Domain in Sorting and Secretion of Aggrecan Core Protein and Ubiquitin-mediated Degradation of Accumulated Mutant Precursors J. Biol. Chem., November 3, 2000; 275(45): 35098 - 35105. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Chen, Y. Wu, V. Lee, C. Kiani, M. E. Adams, Y. Yao, and B. B. Yang The Folded Modules of Aggrecan G3 Domain Exert Two Separable Functions in Glycosaminoglycan Modification and Product Secretion J. Biol. Chem., January 18, 2002; 277(4): 2657 - 2665. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |